The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.

Inclusion Criteria:

• High risk patients
• High doses of other statins
• LDL-C known, starts with Crestor 10 mg
• Permission to use patient data by AstraZeneca (AZ)

primary care